

**FULL DETAILS (Read-only)**

<b>CTRI Number</b>	CTRI/2020/05/024986 [Registered on: 04/05/2020] <b>Trial Registered Prospectively</b>	
<b>Last Modified On:</b>	03/05/2020	
<b>Post Graduate Thesis</b>	No	
<b>Type of Trial</b>	Interventional	
<b>Type of Study Modification(s)</b>	Homeopathy	
<b>Study Design</b>	Single Arm Trial	
<b>Public Title of Study</b>	HOMOEOPATHY IN PREVENTION OF COVID-19	
<b>Scientific Title of Study</b>	EFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHI- A PROSPECTIVE COHORT STUDY	
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Registry</b>
	NIL	NIL
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study) Modification(s)</b>	<b>Name</b>	Dr Debadatta Nayak
	<b>Address</b>	Room no 303 61-65, Sewa Marg, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058 South West DELHI 110058 India
	<b>Phone</b>	09873404012
	<b>Fax</b>	
	<b>Email</b>	drdnayak@gmail.com
<b>Details Contact Person Scientific Query Modification(s)</b>	<b>Name</b>	Dr Anil Khurana
	<b>Address</b>	Room No-408 61-65, Sewa Marg, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058 South West DELHI 110058 India
	<b>Phone</b>	09911127619
	<b>Fax</b>	
	<b>Email</b>	anil23101961@gmail.com
<b>Details Contact Person Public Query Modification(s)</b>	<b>Name</b>	Dr Raj K Manchanda
	<b>Address</b>	Ayurvedic & Unani Tibbia College Campus, Karol Bagh, New Delhi 110005 New Delhi DELHI 110005 India
	<b>Phone</b>	9811014493
	<b>Fax</b>	

	<b>Email</b>	rkmanchanda@gmail.com		
<b>Source of Monetary or Material Support</b>	Central Council for Research in Homoeopathy, New Delhi			
<b>Primary Sponsor</b>	<b>Name</b>	Central Council for Research in Homoeopathy		
	<b>Address</b>	61-65, Sewa Marg, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058 61-65, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058		
	<b>Type of Sponsor</b>	Research institution		
<b>Details of Secondary Sponsor</b>	<b>Name</b>	<b>Address</b>		
	NIL	NIL		
<b>Countries of Recruitment</b>	India			
<b>Sites of Study</b>	No of Sites = 1			
	<b>Contact Person</b>	<b>Name of Site</b>	<b>Site Address</b>	<b>Phone/Fax/Email</b>
	Dr Debadatta Nayak	Hot spots of Covid -19 in Delhi	Central Council for Research in Homoeopathy 61-65, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058 South West	09873404012 drdnayak@gmail.com
<b>Details of Ethics Committee Modification(s)</b>	No of Ethics Committees= 1			
	<b>Name of Committee</b>			<b>Approval Status</b>
	Institutional Ethics Committee-CCRH			Approved
<b>Regulatory Clearance Status from DCGI</b>	<b>Status</b>			
	Not Applicable			
<b>Health Condition / Problems Studied</b>	<b>Health Type</b>	<b>Condition</b>		
	Patients	Coronavirus as the cause of diseases classified elsewhere		
<b>Intervention / Comparator Agent</b>	<b>Type</b>	<b>Name</b>	<b>Details</b>	
	Intervention	Homoeopathic Medicine	Homoeopathic medicine Arsenic album 30c will be given to population residing in hot spots of Red zones of Covid-19 out break. The medicine will be given as medicated globules. 2-4 medicated globules will be given twice daily for 7 days.	
<b>Inclusion Criteria Modification(s)</b>	<b>Age From</b>	1.00 Year(s)		
	<b>Age To</b>	80.00 Year(s)		
	<b>Gender</b>	Both		
	<b>Details</b>	<ul style="list-style-type: none"> <li>• Suspected cases of Covid 19 infection who are asymptomatic</li> <li>• Persons residing in residing in hot spots</li> </ul>		

	<ul style="list-style-type: none"> <li>of Delhi.</li> <li>• Age 1 year &amp; above</li> <li>• Both gender</li> <li>• Willing to give verbal informed consent (keeping in view contagious nature of disease)</li> </ul>				
<b>ExclusionCriteria</b>	<table border="1"> <tr> <td><b>Details</b></td> <td> <ul style="list-style-type: none"> <li>• Pregnant women</li> <li>• Lactating mothers</li> <li>• Immunocompromised individuals on basis of medical history</li> <li>• Symptomatic (similar to COVID-19) cases at quarantine zone.</li> <li>• Not willing to give verbal informed consent</li> </ul> </td> </tr> </table>	<b>Details</b>	<ul style="list-style-type: none"> <li>• Pregnant women</li> <li>• Lactating mothers</li> <li>• Immunocompromised individuals on basis of medical history</li> <li>• Symptomatic (similar to COVID-19) cases at quarantine zone.</li> <li>• Not willing to give verbal informed consent</li> </ul>		
<b>Details</b>	<ul style="list-style-type: none"> <li>• Pregnant women</li> <li>• Lactating mothers</li> <li>• Immunocompromised individuals on basis of medical history</li> <li>• Symptomatic (similar to COVID-19) cases at quarantine zone.</li> <li>• Not willing to give verbal informed consent</li> </ul>				
<b>Method of Generating Random Sequence</b>	Not Applicable				
<b>Method of Concealment</b>	Not Applicable				
<b>Blinding/Masking</b>	Not Applicable				
<b>Primary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>TimePoints</th> </tr> </thead> <tbody> <tr> <td>Confirmation of diagnosis for COVID-19 infection / end of quarantine period as per standard protocol.</td> <td>Every 7th day.</td> </tr> </tbody> </table>	Outcome	TimePoints	Confirmation of diagnosis for COVID-19 infection / end of quarantine period as per standard protocol.	Every 7th day.
Outcome	TimePoints				
Confirmation of diagnosis for COVID-19 infection / end of quarantine period as per standard protocol.	Every 7th day.				
<b>Secondary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>TimePoints</th> </tr> </thead> <tbody> <tr> <td> <ul style="list-style-type: none"> <li>• To compare time to appearance of clinical symptoms of COVID-19 infections.</li> <li>• To compare time to confirmation of diagnosis for COVID-19 (Laboratory findings)</li> </ul> </td> <td>Every 7th day.</td> </tr> </tbody> </table>	Outcome	TimePoints	<ul style="list-style-type: none"> <li>• To compare time to appearance of clinical symptoms of COVID-19 infections.</li> <li>• To compare time to confirmation of diagnosis for COVID-19 (Laboratory findings)</li> </ul>	Every 7th day.
Outcome	TimePoints				
<ul style="list-style-type: none"> <li>• To compare time to appearance of clinical symptoms of COVID-19 infections.</li> <li>• To compare time to confirmation of diagnosis for COVID-19 (Laboratory findings)</li> </ul>	Every 7th day.				
<b>Target Sample Size</b>	<b>Total Sample Size="10000"</b> <b>Sample Size from India="10000"</b>				
<b>Phase of Trial</b>	N/A				
<b>Date of First Enrollment (India)</b>	13/05/2020				
<b>Date of First Enrollment (Global)</b>	No Date Specified				
<b>Estimated Duration of Trial</b>	<b>Years="0"</b> <b>Months="6"</b> <b>Days="0"</b>				
<b>Recruitment Status of Trial (Global) Modification(s)</b>	Not Applicable				
<b>Recruitment Status of Trial (India)</b>	Not Yet Recruiting				

<b>Publication Details</b> <a href="#">Modification(s)</a>	None yet.
<b>Brief Summary</b>	The results of the study will be able to estimate the protective effect of <i>Arsenicum album</i> in COVID 19 prevention. If found effective, this could prove to be a vital contribution in public health care for a disease with high mortality. Further the cost-effectiveness of homoeopathy will enable developing countries in controlling such deadly disease effectively.

Close

---